RESUMEN
OBJECTIVE: The aim: To study the possibilities of increasing the effectiveness of treatment and improving the prognosis of patients with various phenotypes of heart failure when using empagliflozin. PATIENTS AND METHODS: Materials and methods: The analysis of the data regarding the results of existing studies evaluating the clinical benefit and safety of empagliflozin in patients with various phenotypes of heart failure has been conducted. CONCLUSION: Conclusions: In the EMPA-REG OUTCOME study, empagliflozin has demonstrated the ability to improve cardiorenal outcomes and reduce the risk of hospitalization for heart failure in patients with diabetes. The results of the studies (EMPEROR-Preserved, EMPEROR-Reduced, EMPULSE) have shown the clinical advantages of empagliflozin over traditional heart failure therapy, manifested by a reduction in mortality and the number of hospitalizations for heart failure, as well as improvement in quality of life indicators. The clinical benefits of using empagliflozin were observed in patients with chronic heart failure with different left ventricular ejection fraction, as well as in patients with acute heart failure. Empagliflozin is a sodium-glucose co-transporter 2 inhibitor with a convincing evidence base for the treatment of all categories of patients with chronic heart failure, regardless of diabetes status. The results of the conducted studies indicate the unconditional benefit of early initiation of empagliflozin therapy in patients with both chronic and acute heart failure after the stabilization of their condition.
